ABVC BioPharma
ABVC
11 hedge funds and large institutions have $171K invested in ABVC BioPharma in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
38% more funds holding
Funds holding: 8 → 11 (+3)
0.58% less ownership
Funds ownership: 2.41% → 1.83% (-0.58%)
49% less capital invested
Capital invested by funds: $333K → $171K (-$162K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$40K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$25.9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$19.6K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$19.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$233K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$4.3K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$63 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $42.7K | +$34.1K | +33,225 | +151% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $36.3K | – | – | – |
|
|
APP
3
Avantax Planning Partners
Dubuque,
Iowa
| $30.2K | +$40K | +39,000 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $19.5K | +$25.9K | +25,212 | New |
|
|
5
Northern Trust
Chicago,
Illinois
| $14.8K | +$19.6K | +19,135 | New |
|
|
XT
6
XTX Topco
George Town,
Cayman Islands
| $14.7K | +$19.5K | +18,944 | New |
|
7
State Street
Boston,
Massachusetts
| $9.98K | +$13.2K | +12,900 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $2.05K | +$129 | +126 | +5% |
|
|
9
Bank of America
Charlotte,
North Carolina
| $198 | -$4.3K | -4,184 | -94% |
|
|
SAG
10
Spotlight Asset Group
Oakbrook Terrace,
Illinois
| $77 | – | – | – |
|
|
CIC
11
Chase Investment Counsel
Charlottesville,
Virginia
| – | -$233K | -178,377 | Closed |
|
|
12
Wells Fargo
San Francisco,
California
| – | -$63 | -48 | Closed |
|
ABVC Hedge Fund Activity: Q2 2024 in Review
11 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2024, worth a combined $171K — down 49% from $333K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ABVC positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Avantax Planning Partners, opening a new position worth an estimated $40K. The largest seller was Chase Investment Counsel, exiting entirely with an estimated $233K sold.
- 11 institutional investors held ABVC BioPharma (ABVC) as of Q2 2024, up from 8 in Q1 2024.
- Funds reported $171K of ABVC BioPharma stock for Q2 2024, down 49% quarter-over-quarter.
- 5 funds opened new ABVC BioPharma positions in Q2 2024 and 2 closed out, a net change of +3 holders.
- The largest ABVC BioPharma buyer in Q2 2024 was Avantax Planning Partners, an estimated $40K added.
- The largest ABVC BioPharma seller in Q2 2024 was Chase Investment Counsel, an estimated $233K sold.
Based on aggregated 13F filings for Q2 2024.